-

433,236 warrants that were issued in January 2017 were exercised on a cashless basis in exchange for 254,902 shares and an additional 1,250,002 warrants were exercised for $4.6 million;

-

Beyond Cancer’s Board of Directors approved the Beyond Cancer 2022 Equity Incentive Plan (the “BC 2022 Plan”), which allows for awards to officers, directors, employees, and consultants of stock options, stock appreciation rights, restricted stock units, restricted stock and other equity incentives. The vesting terms of the options issued under the BC 2022 Plan are generally four years, unless otherwise specified by the Board or the Award agreement and expire in ten years from the grant date. The BC 2022 Plan has 2,000,000 shares authorized for issuance. On January 3, 2022, Beyond Cancer granted 1,762,000 options to employees and consultants of Beyond Cancer and Beyond Air to purchase its common stock at $2.76 with a 4-year vesting schedule at 25% per year;

-

On January 24, 2022, the Company filed a shelf registration statement on Form S-3 (the “Registration”) registering an indeterminate number of shares of common stock and preferred stock, such indeterminate principal amount of debt securities, such indeterminate number of warrants to purchase common stock, preferred stock and/or debt securities, and such indeterminate number of units as may be sold by the Company from time to time, which together shall have an aggregate initial offering price not to exceed $200,000,000. The Registration was declared effective by the SEC on February 1, 2022;

-

On February 4, 2022, the Company entered into an At-The-Market-Offering Sales Agreement for $50 million utilizing the Company’s January 24, 2022 Registration.